| Abstrakt: |
A study conducted at King Abdulaziz University in Jeddah, Saudi Arabia, focused on the use of rituximab (RTX) for treating pediatric autoimmune diseases. The research aimed to assess the safety and indications of RTX in pediatric patients, analyzing data from 22 patients with various autoimmune conditions. The study found that RTX was commonly used as a second-line treatment following corticosteroids, with infusion-related adverse events occurring in 31.8% of patients. Further research is recommended to optimize treatment strategies and improve patient outcomes in this population. [Extracted from the article] |
